Rachael Cunnick, PA
Physician Assistant · Albuquerque, NMNPI 1972697753
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.2% of the total across 147 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,246 and has fallen 55.4% since, to $555 in 2025. Among physician assistant clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 147 payments — averaging $22.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$460
- Medtronic$403
- Novo Nordisk$398
- Boehringer Ingelheim$366
- Bayer$191
- Abbott$155
- plus $1K from 21 others
What the payments were for
- Consulting fees$702%
- Food & beverage$3,05993%
- Education$1123%
- Other$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 30 | $460 |
| Medtronic | 7 | $403 |
| Novo Nordisk | 25 | $398 |
| Boehringer Ingelheim | 17 | $366 |
| Bayer | 6 | $191 |
| Abbott | 4 | $155 |
| Insulet Corporation | 6 | $154 |
| Phathom Pharmaceuticals, Inc. | 2 | $117 |
| AbbVie | 5 | $112 |
| Sanofi-aventis U.S. LLC | 6 | $106 |
| Merck | 7 | $104 |
| Xeris Pharmaceuticals, Inc. | 5 | $100 |
| Novartis | 4 | $100 |
| Dexcom, Inc. | 3 | $91 |
| Mylan Specialty L.p. | 2 | $62 |
| Viatris Specialty LLC | 2 | $56 |
| AstraZeneca | 3 | $45 |
| Astellas Pharma US Inc | 2 | $43 |
| Baxter Healthcare | 1 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Amgen | 2 | $33 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Recordati_rare_diseases_inc. | 1 | $21 |
| Averitas Pharma Inc. | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Pfizer | 1 | $17 |
| Exeltis, USA Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$291
- Kerendia$125
How this compares
$3,280 in reported general payments places this provider in the 90th percentile of 635 physician assistant providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 75 | $90,806 |
| JardianceEmpagliflozin | 60 | $61,710 |
| OzempicSemaglutide | 52 | $58,162 |
| MounjaroTirzepatide | 36 | $55,969 |
| JanuviaSitagliptin Phosphate | 45 | $37,490 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $34,132 |
| FarxigaDapagliflozin Propanediol | 18 | $17,706 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $15,695 |
| Novolog FlexpenInsulin Aspart | 41 | $14,685 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 74 | $14,049 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 21 | $10,929 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $7,667 |
| Humalog Kwikpen U-100Insulin Lispro | 16 | $4,806 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 40 | $4,147 |
| HumalogInsulin Lispro | 14 | $4,109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $460 | $152,311137 claims |
| Boehringer IngelheimJardiance | $366 | $61,71060 claims |
| Novo NordiskOzempic | $398 | $58,16252 claims |
| MerckJanuvia | $104 | $37,49045 claims |
| AstraZenecaFarxiga | $45 | $17,70618 claims |
| AbbVieSynthroid | $112 | $2,02834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 635 physician assistant providers in New Mexico.
Other physician assistant in Albuquerque
- Leigh HigginsAlbuquerque$10K
- Maria AbeytaAlbuquerque$8K
- Kari LavigneAlbuquerque$8K
- Elizabeth BelitzAlbuquerque$8K
- Desiree BarelaAlbuquerque$6K
- Stephanie BeyesAlbuquerque$5K
- Stephanie GonzalesAlbuquerque$5K
- Miquela WiegelAlbuquerque$5K
- Gabriela PobarAlbuquerque$5K
- Jacklyn ChavezAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.